Older Adult (65+) Archives | MSD Oncology Clinical Trials

English (AU)

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

April 4, 2023

The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator’s choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR) in

Study of Pembrolizumab Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumour Proportion Score ≥50%

March 30, 2023

By Tyler Kalist

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation

Trial Age: Older Adult (65+)

Trial Age: Older Adult (65+)

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

Study of Pembrolizumab Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumour Proportion Score ≥50%